Structure and Function of Recombinant versus Plasma-Derived von Willebrand Factor and Impact on Multimer Pharmacokinetics in von Willebrand Disease

References

• Heijdra JM, Cnossen MH, Leebeek FWG. Current and emerging options for the management of inherited von Willebrand disease. Drugs. 2017;77(14):1531–1547. doi:10.1007/s40265-017-0793-2
   PubMed Web of Science ®Google Scholar
• Furlan M. Von Willebrand factor: molecular size and functional activity. Ann Hematol. 1996;72(6):341–348. doi:10.1007/s002770050184
   PubMed Web of Science ®Google Scholar
• Budde U, Metzner HJ, Müller HG. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease. Semin Thromb Hemost. 2006;32(6):626–635. doi:10.1055/s-2006-949668
   PubMed Web of Science ®Google Scholar
• Furlan M, Robles R, Affolter D, Meyer D, Baillod P, Lämmle B. Triplet structure of von Willebrand factor reflects proteolytic degradation of high molecular weight multimers. Proc Natl Acad Sci U S A. 1993;90(16):7503–7507. doi:10.1073/pnas.90.16.7503
   PubMed Web of Science ®Google Scholar
• Budde U, Pieconka A, Will K, Schneppenheim R. Laboratory testing for von Willebrand disease: contribution of multimer analysis to diagnosis and classification. Semin Thromb Hemost. 2006;32(5):514–521. doi:10.1055/s-2006-947866
   PubMed Web of Science ®Google Scholar
• Goodeve AC. The genetic basis of von Willebrand disease. Blood Rev. 2010;24(3):123–134. doi:10.1016/j.blre.2010.03.003
   PubMed Web of Science ®Google Scholar
• Stockschlaeder M, Schneppenheim R, Budde U. Update on von Willebrand factor multimers: focus on high-molecular-weight multimers and their role in hemostasis. Blood Coagul Fibrinolysis. 2014;25(3):206–216. doi:10.1097/MBC.0000000000000065
   PubMed Web of Science ®Google Scholar
• Federici AB, Bader R, Pagani S, Colibretti ML, De Marco L, Mannucci PM. Binding of von Willebrand factor to glycoproteins Ib and IIb/IIIa complex: affinity is related to multimeric size. Br J Haematol. 1989;73(1):93–99. doi:10.1111/j.1365-2141.1989.tb00226.x
   PubMed Web of Science ®Google Scholar
• Fischer BE, Kramer G, Mitterer A, et al. Effect of multimerization of human and recombinant von Willebrand factor on platelet aggregation, binding to collagen and binding of coagulation factor VIII. Thromb Res. 1996;84(1):55–66. doi:10.1016/0049-3848(96)00161-2
   PubMed Web of Science ®Google Scholar
• Moake JL, Turner NA, Stathopoulos NA, Nolasco LH, Hellums JD. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest. 1986;78(6):1456–1461. doi:10.1172/JCI112736
   PubMed Web of Science ®Google Scholar
• Kragh T, Napoleone M, Fallah MA, Gritsch H, Schneider MF, Reininger AJ. High shear dependent von Willebrand factor self-assembly fostered by platelet interaction and controlled by ADAMTS13. Thromb Res. 2014;133(6):1079–1087. doi:10.1016/j.thromres.2014.03.024
   PubMed Web of Science ®Google Scholar
• Gralnick HR, Williams SB, Morisato DK. Effect of multimeric structure of the factor VIII/von Willebrand factor protein on binding to platelets. Blood. 1981;58(2):387–397. doi:10.1182/blood.V58.2.387.387
   PubMed Web of Science ®Google Scholar
• Leebeek FWG, Eikenboom JCJ. Von Willebrand’s disease. N Engl J Med. 2016;375(21):2067–2080. doi:10.1056/NEJMra1601561
   PubMed Web of Science ®Google Scholar
• Mannucci PM. Treatment of von Willebrand’s disease. N Engl J Med. 2004;351(7):683–694. doi:10.1056/NEJMra040403
   PubMed Web of Science ®Google Scholar
• Federici AB. The use of desmopressin in von Willebrand disease: the experience of the first 30 years (1977–2007). Haemophilia. 2008;14(Suppl1):5–14. doi:10.1111/j.1365-2516.2007.01610.x
   PubMedGoogle Scholar
• Ozgönenel B, Rajpurkar M, Lusher JM. How do you treat bleeding disorders with desmopressin?. Postgrad Med J. 2007;83(977):159–163. doi:10.1136/pgmj.2006.052118
   PubMed Web of Science ®Google Scholar
• Batlle J, López-Fernández MF, Fraga EL, Trillo AR, Pérez-Rodríguez MA. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease. Blood Coagul Fibrinolysis. 2009;20(2):89–100. doi:10.1097/MBC.0b013e3283254570
   PubMed Web of Science ®Google Scholar
• López-Fernández MF, López-Berges C, Corral M, García-Talavera JR, López Borrasca A, Batlle J. Assessment of multimeric structure and ristocetin-induced binding to platelets of von Willebrand factor present in cryoprecipitate and different factor VIII concentrates. Vox Sang. 1987;52(1–2):15–19. doi:10.1111/j.1423-0410.1987.tb02981.x
   PubMed Web of Science ®Google Scholar
• Baxalta US Inc. VONVENDI® (von Willebrand factor [recombinant]) lyophilized powder for solution for intravenous injection [prescribing information]; 2019. Available from: https://www.shirecontent.com/PI/PDFs/VONVENDI_USA_ENG.pdf. Accessed May 20, 2021.
   Google Scholar
• Baxalta Innovations GmbH. Veyvondi summary of product characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/veyvondi-epar-product-information_en.pdf. Accessed May 20, 2021.
   Google Scholar
• Franchini M, Mannucci PM. Von Willebrand factor (Vonvendi®): the first recombinant product licensed for the treatment of von Willebrand disease. Expert Rev Hematol. 2016;9(9):825–830. doi:10.1080/17474086.2016.1214070
   PubMed Web of Science ®Google Scholar
• Turecek PL, Mitterer A, Matthiessen HP, et al. Development of a plasma- and albumin-free recombinant von Willebrand factor. Hamostaseologie. 2009;29(Suppl 1):S32–S38. doi:10.1055/s-0037-1617202
   PubMed Web of Science ®Google Scholar
• Colling ME, Friedman KD, Dzik WH. In vitro assessment of von Willebrand factor in cryoprecipitate, antihemophilic factor/VWF complex (human), and recombinant von Willebrand factor. Clin Appl Thromb Hemost. 2019;25:1076029619873976. doi:10.1177/1076029619873976
   Web of Science ®Google Scholar
• Mannucci PM, Kempton C, Millar C, et al. rVWF Ad Hoc Study Group. Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial. Blood. 2013;122(5):648–657. doi:10.1182/blood-2013-01-479527
   PubMed Web of Science ®Google Scholar
• Turecek PL, Schrenk G, Rottensteiner H, et al. Structure and function of a recombinant von Willebrand factor drug candidate. Semin Thromb Hemost. 2010;36(5):510–521. doi:10.1055/s-0030-1255445
   PubMed Web of Science ®Google Scholar
• Lethagen S, Carlson M, Hillarp A. A comparative in vitro evaluation of six von Willebrand factor concentrates. Haemophilia. 2004;10(3):243–249. doi:10.1111/j.1365-2516.2004.00893.x
   PubMed Web of Science ®Google Scholar
• Reiter RA, Knöbl P, Varadi K, Turecek PL. Changes in von Willebrand factor-cleaving protease (ADAMTS13) activity after infusion of desmopressin. Blood. 2003;101(3):946–948. doi:10.1182/blood-2002-03-0814
   PubMed Web of Science ®Google Scholar
• Turecek PL, Peck RC, Rangarajan S, et al. Recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19. Thromb Res. 2021;201:100–112. doi:10.1016/j.thromres.2021.02.012
   PubMed Web of Science ®Google Scholar
• Hubbard AR, Hamill M, Beeharry M, Bevan SA, Heath AB. SSC sub-committee on von Willebrand factor of ISTH. Value assignment of the WHO 2nd International Standard von Willebrand factor, concentrate (09/182). J Thromb Haemost. 2011;9(8):1638–1640. doi:10.1111/j.1538-7836.2011.04365.x
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Guideline on Reporting the Results of Population Pharmacokinetic Analyses; 2007. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-reporting-results-population-pharmacokinetic-analyses_en.pdf. Accessed November 4, 2022.
   Google Scholar
• US Food and Drug Administration. Population pharmacokinetics: guidance for industry; 2019. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072137.pdf. Accessed November 4, 2022.
   Google Scholar
• Budde U, Schneppenheim R, Eikenboom J, et al. Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD). J Thromb Haemost. 2008;6(5):762–771. doi:10.1111/j.1538-7836.2008.02945.x
   PubMed Web of Science ®Google Scholar
• Gill JC, Castaman G, Windyga J, et al. Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease. Blood. 2015;126(17):2038–2046. doi:10.1182/blood-2015-02-629873
   PubMed Web of Science ®Google Scholar
• Bauer A, Ploder B, Li Z, Mellgård B, Friberg-Hietala S, Wolfsegger M. Population pharmacokinetics and pharmacodynamics of recombinant von Willebrand factor [abstract PB1541]. Res Pract Thromb Haemost. 2020;4(Suppl 1):776–777.
   Google Scholar
• Peyvandi F, Mamaev A, Wang JD, et al. Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery. J Thromb Haemost. 2019;17(1):52–62. doi:10.1111/jth.14313
   PubMed Web of Science ®Google Scholar
• Mannucci PM. New therapies for von Willebrand disease. Blood Adv. 2019;3(21):3481–3487. doi:10.1182/bloodadvances.2019000368
   PubMed Web of Science ®Google Scholar
• Patzke J, Budde U, Huber A, et al. Performance evaluation and multicentre study of a von Willebrand factor activity assay based on GPIb binding in the absence of ristocetin. Blood Coagul Fibrinolysis. 2014;25(8):860–870. doi:10.1097/MBC.0000000000000169
   PubMed Web of Science ®Google Scholar
• Siedlecki CA, Lestini BJ, Kottke-Marchant KK, Eppell SJ, Wilson DL, Marchant RE. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. Blood. 1996;88(8):2939–2950. doi:10.1182/blood.V88.8.2939.bloodjournal8882939
   PubMed Web of Science ®Google Scholar
• Reininger AJ. The function of ultra-large von Willebrand factor multimers in high shear flow controlled by ADAMTS13. Hamostaseologie. 2015;35(3):225–233. doi:10.5482/HAMO-14-12-0077
   PubMed Web of Science ®Google Scholar
• Ledford-Kraemer MR. Analysis of von Willebrand factor structure by multimer analysis. Am J Hematol. 2010;85(7):510–514. doi:10.1002/ajh.21739
   PubMed Web of Science ®Google Scholar
• Dent JA, Galbusera M, Ruggeri ZM. Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of the constituent subunit. J Clin Invest. 1991;88(3):774–782. doi:10.1172/JCI115376
   PubMed Web of Science ®Google Scholar
• Wagner DD, Saffaripour S, Bonfanti R, et al. Induction of specific storage organelles by von Willebrand factor propolypeptide. Cell. 1991;64(2):403–413. doi:10.1016/0092-8674(91)90648-i
   PubMed Web of Science ®Google Scholar
• Berber E. The molecular genetics of von Willebrand disease. Turk J Haematol. 2012;29(4):313–324. doi:10.5505/tjh.2012.39205
   PubMed Web of Science ®Google Scholar